Knoa Pharma Investigator-Initiated Research (IIR) Program — Opioid Overdose Reversal (nalmefene HCl)

About this program

Knoa Pharma LLC offers investigator‑initiated research funding and collaborative support focused on opioid overdose reversal, with priority for studies examining clinical outcomes and resource use associated with nalmefene HCl injections (vial and Zurnai auto‑injector). The current competitive RFP cycle is closed, but unsolicited proposals are accepted and will be evaluated by a medical and scientific review committee; Knoa supports observational and retrospective ED, EMS, and hospital‑based research on reversal efficacy, dosing, recurrence of respiratory depression, precipitated withdrawal, and linkage to addiction services. Applicants should be healthcare professionals or eligible institutions able to provide nalmefene HCl on formulary when required by the study, and funding is contingent on committee review and availability of research funds.